HongyuanPharma(301246.SZ)

Company Encyclopedia
View More
name
HongyuanPharma
301246.SZ
Hubei Hongyuan Pharmaceutical Technology Co., Ltd., together with its subsidiaries, produces and sells pharmaceutical products in China and internationally. The company offers active pharmaceutical ingredients, such as metronidazole, benzoyl metronidazole, dimetrizole, and acyclovir; pharmaceutical intermediates, including imidazole, glyoxylic acid, 2-methyl imidazole, 2-methyl-5-nitroimidazole, sulfate, guanine, diacetyl guanine, and diacetylacyclovir; organic chemical raw materials comprising glyoxal, and oxalic acid; and new energy materials consisting of lithium hexafluorophosphate. It also is involved in the production and sales of triamines, guanine and other products; research and development, production, and sales of pharmaceutical preparations; trading of APIS, pharmaceutical intermediates, organic chemical raw materials, etc.; fluoride salts and other fluorine-containing chemical products; and pharmaceutical wholesale, retail, etc. Hubei Hongyuan Pharmaceutical Technology Co., Ltd.
3.027 T
301246.SZMarket value -Rank by Market Cap -/-

Financial Score

02/01/2026 Update
C
PharmaceuticalsIndustry
Industry Ranking103/222
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE0.33%D
    • Profit Margin0.81%C
    • Gross Margin17.47%D
  • Growth ScoreD
    • Revenue YoY-2.91%D
    • Net Profit YoY-47.34%D
    • Total Assets YoY0.77%C
    • Net Assets YoY-0.25%C
  • Cash ScoreB
    • Cash Flow Margin12413.76%A
    • OCF YoY-2.91%D
  • Operating ScoreD
    • Turnover0.3D
  • Debt ScoreB
    • Gearing Ratio26.53%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Hong Kong Stock Movement: BAO PHARMA-B's full circulation plan triggers a sharp decline in stock price, as the market reassesses liquidity and valuation risks

    BAO PHARMA-B fell 10.06%; Innovent Biologics rose 2.62%, with a transaction volume of HKD 120 million; BeiGene rose 2.45%, with a transaction volume of HKD 63.77 million; CanSino Biologics fell 1.06%, with a transaction volume of HKD 50.03 million; Kelun-Biotech rose 0.71%, with a market capitalization of HKD 92.1 billion

    HK Stock Movers Tracker·
    HK
    02659
    -10.12%
    HK Stock Movers Tracker·
    HK
    02659
    -10.12%

    Weight-Loss Drug Prices Drop in China as Patent Expiry Nears

    Prices of weight-loss drugs in China, including Wegovy and Mounjaro, are dropping as patent expirations approach. Wegovy's price has halved to CNY987.48 from CNY1,893.67, while Mounjaro's presale price is now as low as CNY450, down from CNY2,180. Novo Nordisk's price cuts aim to enhance patient compliance. The patent for semaglutide (Wegovy) expires on March 20, prompting domestic firms to prepare generic versions. This price reduction is expected to impact the industry and future weight-loss drug pricing significantly.

    Yicai·
    Yicai·

    Hongyuan Pharma: Has completed the preparation of kilogram-level sulfide electrolyte precursors and electrolyte samples

    On October 31st, HongyuanPharma stated on the interactive platform that the company has completed the preparation of kilogram-level sulfide electrolyte precursors and electrolyte samples, and is conducting testing and optimization work on solid-state electrolytes

    Zhitong·
    SZ
    301246
    +2.04%
    Zhitong·
    SZ
    301246
    +2.04%

    Hongyuan Pharma released its performance for the first three quarters, with a net loss attributable to the parent company of 1.1002 million yuan

    According to the Zhitong Finance APP, Hongyuan Pharma released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 1.317 billion yuan, a year-on-year decrease of 0.39%. The net loss attributable to shareholders of the listed company was 1.1002 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 24.4001 million yuan. The basic loss per share was 0.0028 yuan

    Zhitong·
    SZ
    301246
    +2.04%
    Zhitong·
    SZ
    301246
    +2.04%

    HongyuanPharma: Actively promoting "third-generation" lithium hexafluorophosphate independent technology

    Hongyuan Pharma is actively promoting its "third-generation" lithium hexafluorophosphate independent technology, aiming to increase its market share in electrolytes. As an innovative enterprise, Hongyuan Pharma invests nearly 70 million yuan in research and development each year, collaborates with multiple universities, and holds 65 patents, forming a comprehensive innovation system. It has built a complete industrial chain in the pharmaceutical field, becoming a major global supplier, and its technology jointly developed with Wuhan University in the new energy sector has reached an internationally advanced level

    Zhitong·
    SZ
    301246
    +2.04%
    Zhitong·
    SZ
    301246
    +2.04%
    © 2026 Longbridge｜Disclaimer